{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:28:02Z","timestamp":1765888082340,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3562-2","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T06:42:28Z","timestamp":1543992148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST)"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2965-9998","authenticated-orcid":false,"given":"Thijs","family":"ten Doesschate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzan P.","family":"van Mens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cees","family":"van Nieuwkoop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne E.","family":"Geerlings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy I. M.","family":"Hoepelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc J. M.","family":"Bonten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"issue":"5","key":"3562_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","volume":"13","author":"AL Flores-Mireles","year":"2015","unstructured":"Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269\u201384.","journal-title":"Nat Rev Microbiol"},{"key":"3562_CR2","first-page":"1","volume-title":"SWAB Guidelines for Antimicrobial Therapy of Complicated Urinary Tract Infections in Adults","author":"Stichting Werkgroep Antibioticabeleid","year":"2013","unstructured":"Stichting Werkgroep Antibioticabeleid. SWAB Guidelines for Antimicrobial Therapy of Complicated Urinary Tract Infections in Adults; 2013. p. 1\u201394. Available from: \n                    http:\/\/www.swab.nl\/richtlijnen"},{"issue":"5","key":"3562_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):103\u201320.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3562_CR4","first-page":"e5","volume":"61","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone G, et al. Ceftazidime-avibactam versus Doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;61(1):e5\u201312.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3562_CR5","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1128\/AAC.00837-08","volume":"53","author":"KG Naber","year":"2009","unstructured":"Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother. 2009;53(9):3782\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"3562_CR6","unstructured":"National institute of Public health and the Environment. Nethmap\/Maran 2018 [Internet]. 2018. Available from: \n                    http:\/\/www.swab.nl\/swab\/cms3.nsf\/viewdoc\/20BCD3983B5C390AC12575850031D33D\n                    \n                  ."},{"issue":"3","key":"3562_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/jac\/dkq465","volume":"66","author":"WE Starre van der","year":"2011","unstructured":"van der Starre WE, van Nieuwkoop C, Paltansing S, van\u2019t Wout JW, Groeneveld GH, Becker MJ, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother. 2011;66(3):650\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3562_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijantimicag.2016.04.014","volume":"48","author":"MP Veve","year":"2016","unstructured":"Veve MP, Wagner JL, Kenney RM, Grunwald JL, Davis SL. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum Beta-lactamase urinary tract infections. Int J Antimicrob Agents. 2016;48(1):56\u201360.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"3562_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1179\/joc.2010.22.5.355","volume":"22","author":"S Senol","year":"2010","unstructured":"Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, et al. Carbapenem versus Fosfomycin Tromethanol in the treatment of extended-Spectrum Beta-lactamase-producing Escherichia Coli -related complicated lower urinary tract infection. J Chemother. 2010;22(5):355\u20137.","journal-title":"J Chemother"},{"key":"3562_CR10","unstructured":"Surber C. Product monograph of monurol. 2016;(version 4.0). Available from: \n                    http:\/\/www.paladin-labs.com\/our_products\/Monurol-Sachet-PM-En.pdf"},{"issue":"3","key":"3562_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-0030-1267062","volume":"1","author":"J Dettori","year":"2010","unstructured":"Dettori J. The random allocation process: two things you need to know. Evid Based Spine Care J. 2010;1(3):7\u20139.","journal-title":"Evid Based Spine Care J"},{"issue":"1","key":"3562_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12916-017-0835-3","volume":"15","author":"C Nieuwkoop van","year":"2017","unstructured":"van Nieuwkoop C, van der Starre WE, Stalenhoef JE, van Aartrijk AM, van der Reijden TJK, Vollaard AM, et al. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC Med. 2017;15(1):70.","journal-title":"BMC Med"},{"issue":"9840","key":"3562_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","volume":"380","author":"T Sandberg","year":"2012","unstructured":"Sandberg T, Skoog G, Hermansson AB, Kahlmeter G, Kuylenstierna N, Lannerg\u00e5rd A, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012;380(9840):484\u201390.","journal-title":"Lancet"},{"issue":"7","key":"3562_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/cid\/civ436","volume":"61","author":"ML Grayson","year":"2015","unstructured":"Grayson ML, Macesic N, Trevillyan J, Ellis AG, Zeglinski PT, Hewitt NH, et al. Fosfomycin for treatment of prostatitis: new tricks for old dogs. Clin Infect Dis. 2015;61(7):1141\u20133.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3562_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","volume":"10","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum Beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43\u201350.","journal-title":"Lancet Infect Dis"},{"issue":"9981","key":"3562_CR16","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385(9981):1949\u201356.","journal-title":"Lancet"},{"issue":"5","key":"3562_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/1740774512453220","volume":"9","author":"DJ Bratton","year":"2012","unstructured":"Bratton DJ, Williams HC, Kahan BC, Phillips PP, Nunn a J. When inferiority meets non-inferiority: implications for interim analyses. Clin Trials. 2012;9(5):605\u20139.","journal-title":"Clin Trials"},{"issue":"3","key":"3562_CR18","doi-asserted-by":"publisher","first-page":"e007363","DOI":"10.1136\/bmjopen-2014-007363","volume":"5","author":"C Rosso-Fern\u00e1ndez","year":"2015","unstructured":"Rosso-Fern\u00e1ndez C, Sojo-Dorado J, Barriga A, Lav\u00edn-Alconero L, Palacios Z, L\u00f3pez-Hern\u00e1ndez I, et al. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open. 2015;5(3):e007363.","journal-title":"BMJ Open"},{"key":"3562_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/43.4.601","volume":"43","author":"F Sevinc","year":"1999","unstructured":"Sevinc F, Prins JM, Koopmans R, Langendijk PNJ, Bossuyt PMM, Dankert J, Speelman P. Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. J Antimicrob Chemother. 1999;43:601\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"3901","key":"3562_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1126\/science.166.3901.122","volume":"166","author":"D Hendlin","year":"1969","unstructured":"Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science. 1969;166(3901):122\u20133.","journal-title":"Science"},{"issue":"5","key":"3562_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000239140","volume":"39","author":"Tom Bergan","year":"1993","unstructured":"Bergan T, Thorsteinsson SB, Albini E. Pharmacokinetic profile of fosfomycin trometamol. Chemotherapy Jan;39(5):297\u2013301.","journal-title":"Chemotherapy"},{"issue":"4","key":"3562_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","volume":"47","author":"KZ Vardakas","year":"2016","unstructured":"Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47(4):269\u201385.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"3562_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.cmi.2017.08.023","volume":"24","author":"RA Wijma","year":"2018","unstructured":"Wijma RA, Koch BCP, van Gelder T, Mouton JW. High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers. Clin Microbiol Infect. 2018;24(5):528\u201332.","journal-title":"Clin Microbiol Infect"},{"key":"3562_CR24","first-page":"AAC.00775-17","volume-title":"Pharmacokinetics, Safety, and Tolerability of Single Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers. Antimicrob Agents Chemother [Internet]","author":"E Wenzler","year":"2017","unstructured":"Wenzler E, Ellis-Grosse EJ, Rodvold KA. Pharmacokinetics, Safety, and Tolerability of Single Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers. Antimicrob Agents Chemother [Internet]; 2017. p. AAC.00775-17. Available from: \n                    http:\/\/aac.asm.org\/lookup\/doi\/10.1128\/AAC.00775-17"},{"key":"3562_CR25","volume-title":"NethMap\/Maran 2017; Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands [internet]","author":"The Dutch Foundation of the Working Party on Antibiotic Policy","year":"2017","unstructured":"The Dutch Foundation of the Working Party on Antibiotic Policy. NethMap\/Maran 2017; Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands [internet]. 2017. Available from: \n                    http:\/\/www.swab.nl\/swab\/cms3.nsf\/viewdoc\/20BCD3983B5C390AC12575850031D33D"},{"issue":"7","key":"3562_CR26","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s11255-015-1018-9","volume":"47","author":"YH Cho","year":"2015","unstructured":"Cho YH, Il JS, Chung HS, Yu HS, Hwang EC, Kim SO, et al. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. Int Urol Nephrol. 2015;47(7):1059\u201366.","journal-title":"Int Urol Nephrol"},{"key":"3562_CR27","doi-asserted-by":"crossref","unstructured":"van den Bijllaardt W, Schijffelen MJ, Bosboom RW, Cohen Stuart J, Diederen B, Kampinga G, et al. Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion. J Antimicrob Chemother [Internet]. 2018;(July):2380\u20132387. Available from: \n                    https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dky214\/5047839","DOI":"10.1093\/jac\/dky214"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3562-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3562-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3562-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T19:11:57Z","timestamp":1575486717000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3562-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3562"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3562-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"20 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The medical ethics committee of the University Medical Centre Utrecht approved the study protocol, followed by the Institutional Scientific Boards of the following Dutch participating centres:","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"626"}}